Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Cultural Diversity and Kidney Replacement Therapy Outcomes in Australia" [<i>Kidney International Reports</i> Volume 11, Issue 3, March 2026, 103743].

Kidney international reports·2026
Same author

Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Telitacicept in Recurrent IgA Nephropathy After Kidney Transplantation: Encouraging Signal, Cautious Interpretation.

Kidney international reports·2026
Same author

Sleep Hygiene Among People With CKD.

Kidney international reports·2026
Same author

Cultural Diversity and Kidney Replacement Therapy Outcomes in Australia.

Kidney international reports·2026
Same author

Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

The New England journal of medicine·2025

Related Experiment Video

Updated: Jun 5, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

IgA nephropathy in India: what we do know.

Bobby Chacko1

  • 1Department of Nephrology, St John's Medical College Hospital, Bangalore, India. bobcha@hotmail.com

Renal Failure
|January 12, 2011
PubMed
Summary

IgA nephropathy (IgAN) in India presents with low incidence but high severity, leading to poor patient outcomes compared globally. Further research is crucial to understand and address this concerning pattern in the Indian population.

Area of Science:

  • Nephrology
  • Immunology
  • Genetics

Background:

  • IgA nephropathy (IgAN) is a primary glomerulonephritis with a significant impact in India.
  • Despite not being the most common GN, IgAN outcomes in India are worse than in other regions.

Purpose of the Study:

  • To systematically review existing Indian research on IgAN.
  • To compare IgAN data between India and other countries.

Main Methods:

  • Systematic review of basic and clinical research on IgAN in India.
  • Comparative analysis of Indian IgAN data with international findings.

Main Results:

  • IgAN accounts for 7-16% of Indian biopsy samples, potentially underrepresenting its prevalence.

More Related Videos

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
14:18

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

Related Experiment Videos

Last Updated: Jun 5, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
14:18

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

  • Common presentations include nephrotic syndrome and renal failure, with alarmingly low renal survival rates.
  • The DD genotype of the angiotensin-1 converting enzyme (ACE) gene may be a risk factor for IgAN in Indians; recurrence post-transplant is observed but indolent.

    • Conclusions:

    • IgAN in India is characterized by low incidence but severe presentation and poor outcomes.
    • The reasons for the poor prognosis in India remain unclear.
    • In-depth basic research and multicenter clinical trials are essential to elucidate the unique patterns of IgAN in India.